Invasive mould diseases (IMDs) are often encountered in haematologic patients who undergo chemotherapy or who require allogeneic haematopoietic stem cell transplantation (allo-HSCT), and still represent a challenge for physicians. The availability of antifungals with different targets has set the foundation to improve the outcomes of patients with IMDs and also to develop innovative therapeutic approaches. Among these, using combinations of antifungal drugs is an attractive option for reasons such as the broader spectrum of activity, synergy between compounds with different targets, and a reduced risk of fungal resistance. In addition, in vitro studies and animal models have provided evidence supporting the use of combination strategies. Although no controlled, well-powered, prospective clinical trials are yet available to demonstrate the superiority of combination versus monotherapy, the persistently high mortality rate associated with IMDs has stimulated the use of combinations of antifungal drugs, both in adult and paediatric patients. In this paper, we review the recent published literature on combination therapy for the treatment of IMDs in adult and paediatric haematologic patients.
|Data di pubblicazione:||2015|
|Titolo:||Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data|
|Autori:||Candoni, Anna; Aversa, Franco; Busca, Alessandro; Cesaro, Simone; Girmenia, Corrado; Luppi, Mario; Rossi, Giuseppe; Venditti, Adriano; Nosari, Anna Maria; Pagano, Livio|
|Digital Object Identifier (DOI):||10.1179/1973947814Y.0000000224|
|Appare nelle tipologie:||Articolo su rivista|
File in questo prodotto:
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris